









This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/bjh.16852 
This article is protected by copyright. All rights reserved 
 
DR. JEFF K DAVIES (Orcid ID : 0000-0002-3192-6995) 
PROF. JOHN G GRIBBEN (Orcid ID : 0000-0002-8505-7430) 
DR. JOHN CHARLES RICHES (Orcid ID : 0000-0002-3425-7686) 
 
 
Article type      : Letters 
 
 
Corresponding author mail id:- j.riches@qmul.ac.uk 
 
Title: Clinical Outcome of Coronavirus Disease 2019 in Haemato-oncology 
Patients 
 
To the Editor: 
 
Since being identified in China in December 2019, coronavirus disease 2019 (Covid-
19) has rapidly evolved into a global pandemic with over 4 million cases and more 
than 270,000 deaths.(1) Following the first reported cases in the United Kingdom 
(UK) in late January 2020, numbers have continued to rise with 223,060 cases and 
32,065 deaths reported as of 11th May 2020.(2) Initial reports from China have 
indicated that Covid-19 has an overall mortality rate of 1.4%. However, the prognosis 
varies widely between groups, with age over 60 years and underlying conditions 
including hypertension, diabetes, cardiovascular disease and cancer identified as 
risk factors for severe disease and death.(3) The initial reports from China show that 
patients with cancer are over-represented among individuals who develop severe 
Covid-19 after contracting the virus.(4) Patients with haematological malignancies 
are expected to be at increased risk of adverse outcomes from this viral infection, 
due being immunosuppressed as a consequence of the underlying cancer, and from 
the effects of therapy. This has led to a variety of recommendations to reduce the 
risk from Covid-19, including “shielding” by self-isolating at home for prolonged 
periods, and alterations to therapy such as delaying or even omitting chemotherapy, 
radiotherapy or transplantation.(5-8) However, at the time of writing there is virtually 
no published data on the impact of Covid-19 in patients with haematological 
malignancies.  
 
We identified 35 adult patients with a known diagnosis of a haematological 
malignancy under the care of Barts Cancer Centre who developed a laboratory-
confirmed Covid-19 infection between 11th March and 11th May, 2020. A confirmed 
case of Covid-19 was defined by a positive result on a reverse-transcriptase–
polymerase-chain-reaction (RT-PCR) assay of a specimen collected on a 
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patient had at least 14 days of follow-up. The demographic and clinical 
characteristics of the patients are shown in Table 1. The median age of the patients 
was 69 years; 66% were men. 12 patients had multiple myeloma, 5 patients had 
chronic lymphocytic leukaemia, 4 patients respectively had diffuse large B cell 
lymphoma and acute lymphoblastic leukaemia, 3 patients had follicular lymphoma, 2 
patients had acute myeloid leukaemia, along with 1 patient with each of aplastic 
leukaemia, myelofibrosis, monoclonal gammopathy of undetermined significance, 
mantle cell lymphoma and myelodysplastic syndrome. 54% of patients were known 
to have pre-existing hypogammaglobulinaemia at baseline. 24 (69%) patients were 
on active treatment at the time of Covid-19 diagnosis; the treatment history for each 
case is given in the data supplement. Many patients had co-existing chronic medical 
conditions, most frequently hypertension (29%), chronic kidney disease (14%) and 
diabetes mellitus (15%). The most common symptoms were fever (77%), cough 
(60%) and shortness of breath (54%).  
 
Table 2 shows correlation of clinical and laboratory findings with outcome. As of 11th 
May, 14 (40%) patients had died and 21 (60%) patients had recovered. Age was 
most significantly associated with outcome in our series with all but one of the 
patients who died being 70 years or older at the time of Covid-19 diagnosis. The 
number of co-existing comorbidities such as hypertension, chronic kidney disease or 
diabetes was also predictive of outcome with patients who died having significantly 
more concurrent diagnoses than patients who recovered. This reflects the 
observations seen in initial studies where the elderly and those with underlying 
conditions were at a significantly higher risk for severe disease and death.(3) 
Importantly we did not see a correlation between active treatment and outcome in 
our series. Furthermore, we document 15 patients who have recovered from Covid-
19 despite being on treatment at the time of diagnosis of their infection, including 
patients on highly immunosuppressive regimens such as R-CHOP for lymphoma, 
induction regimens for acute leukaemia and triplet combinations for myeloma. In 
terms of laboratory parameters hypoxia on admission and a highly elevated C-
reactive protein level were predictive of a poor outcome. In contrast, there was no 
association between admission haemoglobin concentration, platelet count or 
neutrophil:lymphocyte ratio and outcome. Perhaps unexpectedly, patients who 
recovered had a lower neutrophil and lymphocyte count on admission than the 
patients who died. This probably reflects inclusion of younger fitter patients receiving 
more myelosuppressive and lymphodepleting therapy, who nevertheless went on to 
recover from their infection. However, this highlights that the impact of Covid-19 on 
haematological parameters such as a lymphopenia, or the prognostic utility of 
neutrophil:lymphocyte ratio may be confounded by other factors in haemato-
oncology patients.(9, 10) 
 
Given the focus on hospital-based testing for suspected Covid-19 in the UK, a crude 
case fatality rate in a comparable group of hospital-assessed patients of 14.4% can 
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case fatality rate of 40% in haemato-oncology patients, which is comparable to the 
proportion of patients with cancer who reached a composite endpoint of requiring 
admission to intensive care, invasive ventilation or death in a previous report.(4) 
Therefore our patients who developed Covid-19 have an approximately 3-fold 
increased risk of death compared to the general population. Due to the current lack 
of widespread community testing for Covid-19 in the UK, the case fatality rate 
reported here is likely to be an overestimate within this patient group. While only 
patients with laboratory-confirmed Covid-19 were included in our series, we were 
aware of other haemato-oncology patients who had mild symptoms and were 
advised to self-isolate at home rather than attend hospital for assessment, and were 
therefore not tested for SARS-CoV-2. Furthermore, it is likely other patients with 
no/mild symptoms have not presented to our network.  
 
Our study does have several limitations, including the relatively small sample size 
and lack of data on patients who developed Covid-19 in the community and were not 
tested.  Ultimately, some of these questions will be addressed by larger multi-
national and registry studies. However, given the rapidly evolving nature of the global 
Covid-19 pandemic there is a place for case series in guiding haematological 
practice during these challenging times. Our data demonstrate that while patients 
with haematological cancers have worse outcomes after Covid-19 than the 
background population, the majority still survive.  
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Table 1. Clinical characteristics of the Patients  
Clinical Characteristics of the Patients Patients  
Enrolment Site – no. (%)  
      Barts Health NHS Trust 
      Homerton University Hospital NHS Foundation Trust 
      The London Clinic 
      Southend University Hospital NHS Foundation Trust 
      Barking, Havering and Redbridge University Hospitals NHS Trust 
      Basildon and Thurrock University Hospitals NHS Foundation Trust  







Median age (range) - years 69 (31 – 87) 
Sex – no. (%) 
      Male 
      Female 
N = 35 
23 (66%) 
12 (34%) 
Haemato-oncological diagnosis – no. (%) 
      Multiple myeloma 
      Chronic lymphocytic leukaemia/Small lymphocytic lymphoma 
      Diffuse large B cell lymphoma 
      Acute lymphoblastic leukaemia 
      Follicular lymphoma 
      Acute myeloid leukaemia 
      Mantle cell lymphoma 
      Aplastic anaemia 
      Myelofibrosis 
      Myelodysplastic syndrome 
      Monoclonal gammopathy of undetermined significance 













      Yes 
      No 
N = 24 
13 (54%) 
11 (46%) 
Number of lines of treatment – no. (%) 
      Untreated  
      1st line treatment 
      2nd line treatment 
      > 3rd line treatment 





Patients on active treatment at time of Covid-19 diagnosis 
      Yes 
      No 
N = 35 
24 (69%) 
11 (31%) 
Co-existing disorders – no. (%) 
      Hypertension 
      Renal failure 
      Diabetes 
      Previous cancer 
      Previous Venous thromboembolism 
      Atrial fibrillation 
      Ischaemic heart disease 
      Asthma 
      Valvular Heart Disease 
      Chronic lung disease/COPD 
      Co-existing non-haematological cancer 
      Hyper-obstructive cardiomyopathy 
      Liver fibrosis 














Symptoms – no. (%) 
      Fever 
      Cough 
      Shortness of Breath 
      Weakness 
      Myalgia 
      Diarrhoea 
      Coryza 
      Chest pain 
      Headache 
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      Vasovagal episode 





Table 2. Correlation of clinical and laboratory findings with outcome 
Clinical/laboratory parameter Patients P value 
Median age (range) - years 
     Deceased patients (N = 14) 
     Recovered patients (N = 21) 
 
78 (33 – 87) 
59 (31 – 81) 
 
<0.0001 
Patients on treatment at Covid-19 diagnosis – no. (%) 
     Deceased patients (N = 14) 






Patients on > 3rd line treatment – no. (%) 
     Deceased patients (N = 14) 






Median number of major comorbidities 
     Deceased patients (N = 14) 
     Recovered patients (N = 21) 
 
2.5 (1 – 4) 
1 (0 – 2) 
 
<0.0001 
Median admission oxygen saturations (%) 
     Deceased patients (N = 13) 
     Recovered patients (N = 17) 
 
88 (60 – 100) 
96 (88 – 100) 
 
0.0038 
Median admission haemoglobin (g/dL) 
     Deceased patients (N = 12) 
     Recovered patients (N = 17) 
 
108 (53 – 123) 
103 (78 – 146) 
 
0.46 
Median admission neutrophil count (x 109/L) 
     Deceased patients (N = 12) 
     Recovered patients (N = 17) 
 
5.0 (1.6 – 14.2) 
2.1 (0.1 – 10.1) 
 
0.0020 
Median admission lymphocyte count (x 109/L) 
     Deceased patients (N = 12) 
     Recovered patients (N = 17) 
 
1.2 (0.3 – 306) 




Median admission platelet count (x 109/L) 
     Deceased patients (N = 12) 
     Recovered patients (N = 17) 
 
130 (21 – 244) 
144 (36 – 280) 
 
0.80 
Median admission neutrophil:lymphocyte ratio 
     Deceased patients (N = 12) 
     Recovered patients (N = 17) 
 
6.1 (0.0 – 20.7) 
3.7 (0.3 – 14.4) 
 
0.49* 
Median maximum c-reactive protein (mg/L) 
     Deceased patients (N = 13) 
     Recovered patients (N = 17) 
 
279 (88 – 367) 




*A patient with a lymphocytosis due to CLL was excluded for these calculations. 
